Provided by Tiger Trade Technology Pte. Ltd.

Bio-Rad Laboratories

385.90
-1.7975-0.46%
Volume:90.72K
Turnover:34.92M
Market Cap:10.33B
PE:46.73
High:393.00
Open:393.00
Low:382.13
Close:387.70
52wk High:396.23
52wk Low:236.73
Shares:26.76M
Float Shares:20.89M
Volume Ratio:0.51
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.26
EPS(LYR):27.85
ROE:3.11%
ROA:1.66%
PB:1.44
PE(LYR):13.86

Loading ...

S&P 500 Futures Drop in Premarket Trading; on Semiconductor, Davita Lag

Dow Jones
·
Jun 26

CEL-SCI, Saudi Amarox hold strategic agreement signing at BIO 2026

TIPRANKS
·
Jun 24

Contract Research Organization Stocks Surge as BIO Conference Highlights Chinese CXO Global Competitiveness; Pharmaceutical Sector Openness Achieves New Milestone

Stock News
·
Jun 24

Neurizon strengthens NUZ-001 ALS case with new mechanistic data at BIO 2026

TIPRANKS
·
Jun 23

VERAXA Biotech (NASDAQ: VRXA) Showcases BiTAC Cancer Platforms Ahead of BIO International Convention

TIPRANKS
·
Jun 22

Thermo Fisher to showcase new capabilities at BIO International 2026

TIPRANKS
·
Jun 22

Genflow’s Chair to Spotlight Longevity and RNA Therapeutics at BIO 2026

TIPRANKS
·
Jun 22

Bio Protocol launches AI research hub to challenge grant gatekeepers

cryptonews
·
Jun 20

BioHarvest Sciences to Showcase Botanical Synthesis at 2026 BIO International Convention

TIPRANKS
·
Jun 19

How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story

Simply Wall St.
·
Jun 19

BIO-key’s Fireside Chat at Maxim Group Defense Tech Conf. to Webcast Thur. June 25 at 4pm ET

GlobeNewswire
·
Jun 18

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026

GlobeNewswire
·
Jun 18

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

GlobeNewswire
·
Jun 17

Silexion Therapeutics to Attend BIO International Convention 2026

GlobeNewswire
·
Jun 17

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

GlobeNewswire
·
Jun 15

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

GlobeNewswire
·
Jun 13

Does New MicroVal Approval Clarify Bio-Rad (BIO)’s Competitive Edge in Food Safety Testing?

Simply Wall St.
·
Jun 11

BIO-key Faces Heightened Nasdaq Delisting and Compliance Risks

TIPRANKS
·
Jun 11

BIO-key International Receives Nasdaq Non-Compliance Notice Over Late 10-Q Filing

MT Newswires Live
·
Jun 11

BIO-key receives noncompliance notification from Nasdaq

TIPRANKS
·
Jun 11